Last mentioned: Mar 25, 2026
Keytruda Patent Expiration
The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
Keytruda Patent Expiry
Merck faces biosimilar competition for its top-selling immunotherapy drug.
Keytruda Patent Cliff
Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
Keytruda Patent Cliff
Expected loss of exclusivity for Merck's top-selling cancer drug, Keytruda.
Pipeline Integration
Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
Expected Closing
Anticipated completion of the acquisition following regulatory and shareholder approvals.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Expected Closing
Anticipated completion of the acquisition following regulatory reviews.
Acquisition Announced
Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
Acquisition Announced
Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout.
Acquisition Announcement
Merck announces definitive agreement to buy Terns for $6.7 billion.
Terns Acquisition Announced
Merck agrees to buy Terns Pharmaceuticals for $6.7 billion to acquire TERN-701.
Clinical Progress
Terns Pharmaceuticals advances TERN-701 through early-stage clinical trials for CML.
Prometheus Acquisition
Merck buys Prometheus Biosciences for $10.8 billion to bolster its immunology pipeline.
Acceleron Acquisition
Merck acquires Acceleron Pharma for $11.5 billion to expand in cardiovascular disease.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.